Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06158113 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study
A Phase 2 study of Oral Lichen Planus and Lichen Planus, Oral, sponsored by University of North Carolina, Chapel Hill.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06158113 is a Phase 2 study of Oral Lichen Planus and Lichen Planus, Oral that is active but no longer recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 10 participants, below the 22-participant average among 3 other Oral Lichen Planus trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06158113, a Phase 2 study of Oral Lichen Planus and Lichen Planus, Oral, is active but no longer recruiting, sponsored by University of North Carolina, Chapel Hill.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn the effects of baricitinib (the study drug) in patients with Oral Lichen Planus. The main questions it aims to answer are: * What is the efficacy of baricitinib in treating moderate to severe Oral Lichen Planus? * Can baricitinib treatment in Oral Lichen Planus change quality of life? * What side effects do patients with Oral Lichen Planus experience when treated with baricitinib? Participants will be required to come in to monthly visits for up to eight months. During visits, participants will be: * Evaluated for the extent of their disease * Asked to fill out a questionnaire about their quality of life * Given baricitinib for them to take at home for six months * Evaluated for any potential side experienced while on treatment * Asked to return 1 month after completing treatment
Conditions Studied
Interventions
- DRUG Baricitinib 4 milligram Oral Tablet
Study Locations (1)
North Carolina
- UNC Dermatology and Skin Cancer Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06158113
The ClinicalTrials.gov registry entry for NCT06158113 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 22-participant average among 3 other Oral Lichen Planus trials with a reported enrollment target (55% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Oral Lichen Planus appearing as the primary indexed condition, and to 1 intervention - of which Baricitinib 4 milligram Oral Tablet is the first listed.
NCT06158113 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06158113 about?
NCT06158113 is a clinical study titled "Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study". The goal of this clinical trial is to learn the effects of baricitinib (the study drug) in patients with Oral Lichen Planus. The main questions it aims to answer are: * What is the efficacy of baricitinib in treating moderate to severe Oral Lichen Planus? * Can baricitinib treatment in Oral Lichen ...
What is the current status of trial NCT06158113?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2024-03-13. Estimated completion is 2026-09.
What conditions does trial NCT06158113 study?
This clinical trial studies the following conditions: Oral Lichen Planus, Lichen Planus, Oral, Lichen Planus, Mucosal.
What interventions are being tested in trial NCT06158113?
The interventions under investigation include: Baricitinib 4 milligram Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT06158113?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06158113 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Lichen Planus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.